In recent years, the hepatic antiviral drugs market is anticipated to grow rapidly during the forecast period. According to the 2019 study "Burden of Liver Diseases in the World," liver illness causes roughly 2 million fatalities per year worldwide, with 1 million deaths owing to cirrhosis complications and 1 million deaths due to viral hepatitis and hepatocellular cancer. Cirrhosis is the 11th most prevalent cause of mortality globally, while liver cancer is the 16th most common cause of death. In addition, chronic liver disease mortality in the United States is predicted to climb, owing to an increase in non-alcoholic fatty liver disease (NAFLD). The increased prevalence of liver illnesses aided in the market's expansion.
